These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6467680)

  • 1. Effect of nandrolone decanoate on Sjögren's syndrome like disorders in NZB/NZW mice.
    Schot LP; Verheul HA; Schuurs AH
    Clin Exp Immunol; 1984 Sep; 57(3):571-4. PubMed ID: 6467680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of nandrolone decanoate, tibolone, lynestrenol and ethylestrenol on Sjögren's syndrome-like disorder in NZB/W mice.
    Verheul HA; Schot LP; Schuurs HW
    Clin Exp Immunol; 1986 May; 64(2):243-8. PubMed ID: 3742875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of Sjögren's disease in NZB/NZW F1 hybrid mice with azathioprine: a two-stage study.
    Yeoman CM; Franklin CD
    Clin Exp Rheumatol; 1994; 12(1):49-53. PubMed ID: 8162642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
    Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
    Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of nandrolone, testosterone and their decanoate esters on murine lupus.
    Verheul HA; Stimson WH; den Hollander FC; Schuurs AH
    Clin Exp Immunol; 1981 Apr; 44(1):11-7. PubMed ID: 6973425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of sulphasalazine as a treatment modality in Sjögren's disease in NZB/NZW F1 hybrid mice.
    Yeoman CM; Franklin CD
    Clin Exp Rheumatol; 1996; 14(1):53-7. PubMed ID: 8697658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment of anti-CD4CD25 T cell monoclonal antibody exacerbates sialoadenitis in submandibular glands during the early life in lupus-prone female NZB x NZWF mice.
    Hayashi T; Adachi C; Hasegawa K
    J Oral Pathol Med; 2009 Feb; 38(2):234-40. PubMed ID: 19141059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
    Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
    Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effect of Ophiopogon japonicus polysaccharides on an autoallergic mouse model for Sjogren's syndrome by regulating the Th1/Th2 cytokine imbalance.
    Wang Y; Yan T; Shen J; Guo H; Xiang X
    J Ethnopharmacol; 2007 Nov; 114(2):246-53. PubMed ID: 17888600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local suppression of IL-21 in submandibular glands retards the development of Sjögren's syndrome in non-obese diabetic mice.
    Liu H; Liu G; Gong L; Zhang Y; Jiang G
    J Oral Pathol Med; 2012 Nov; 41(10):728-35. PubMed ID: 22643047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exocrinopathy resembling Sjögren's syndrome induced by a murine retrovirus.
    Suzuki K; Makino M; Okada Y; Kinoshita J; Yui R; Kanazawa H; Asakura H; Fujiwara M; Mizuochi T; Komuro K
    Lab Invest; 1993 Oct; 69(4):430-5. PubMed ID: 8231110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nandrolone decanoate (deca-durabolin) in primary Sjögren's syndrome: a double blind pilot study.
    Drosos AA; van Vliet-Dascalopoulou E; Andonopoulos AP; Galanopoulou V; Skopouli FN; Moutsopoulos HM
    Clin Exp Rheumatol; 1988; 6(1):53-7. PubMed ID: 3396249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sjögren's syndrome in MRL/l and MRL/n mice.
    Hoffman RW; Alspaugh MA; Waggie KS; Durham JB; Walker SE
    Arthritis Rheum; 1984 Feb; 27(2):157-65. PubMed ID: 6421291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of cytotoxic autoantibody to lacrimal gland cells in NZB/W mice.
    Ohashi Y; So SK; Minasi PN; Tabbara KF
    Invest Ophthalmol Vis Sci; 1985 Feb; 26(2):214-9. PubMed ID: 3972503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506.
    Yang J; Shikata N; Yasuda T; Matsuzawa A; Tsubura A
    Pathol Int; 1999 Feb; 49(2):133-40. PubMed ID: 10355966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and quantitative changes of immune cells of ageing NZB mice treated with nandrolone decanoate. I. Effect on survival and autoantibody development.
    Bruley-Rosset M; Dardenne M; Schuurs A
    Clin Exp Immunol; 1985 Dec; 62(3):630-8. PubMed ID: 3878753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice.
    Thompson C; Jacobsen H; Pomeranz Krummel D; Nagai K; Cooke A
    Autoimmunity; 2004 Dec; 37(8):549-54. PubMed ID: 15763917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical characterization of sialadenitis in NZB X NZW F1 mice.
    Jonsson R; Tarkowski A; Bäckman K; Klareskog L
    Clin Immunol Immunopathol; 1987 Jan; 42(1):93-101. PubMed ID: 3791713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
    Tsubota K; Saito I; Ishimaru N; Hayashi Y
    Invest Ophthalmol Vis Sci; 1998 Aug; 39(9):1551-9. PubMed ID: 9699544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bromhexine on the kidney lesions in NZB-NZW-F1 mice.
    Prause JU; Elling F; Jensen OA; Manthorpe R
    Scand J Rheumatol Suppl; 1986; 61():286-90. PubMed ID: 3473646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.